Research into personalized cancer vaccines is booming. Explore the ongoing clinical trials in the country in the list below.
|Phase||Cancer type||Institution/ Company Sponsors||Vaccine Platform||Patient Status||Patient Accrual Target|
|NCT03568058||Phase 1||Advanced cancers||University of California, San Diego||Synthetic long peptide||Recruiting||10|
|NCT03199040||Phase 1||Breast cancer||Washington University School of Medicine, MedImmune||DNA||Recruiting||24|
|NCT02348320||Phase 1||Breast cancer||Washington University School of Medicine||DNA||Recruiting||30|
|NCT03121677||Phase 1||Follicular lymphoma||Washington University School of Medicine, Bristol-Myers Squibb||Synthetic long peptide||Recruiting||20|
|NCT03122106||Phase 1||Pancreatic cancer||Washington University School of Medicine, National Cancer Institute (NCI)||DNA||Recruiting||15|
|NCT03532217||Phase 1||Prostate cancer||Washington University School of Medicine, Bristol-Myers Squibb||DNA||Recruiting||20|
|NCT03598816||Phase 2||Renal cell carcinoma||Washington University School of Medicine, MedImmune||DNA||Not yet recruiting||48|
Read the full story.
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?